Rare diseases
Investigational molecules
Locations
703 conditions with trials, the busiest first
3 898 trials across Europe, recruiting first
Testing 18F-DPA-714 PET scan as a marker of brain inflammation in patients with autoimmune encephalitis
FranceA study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.
AustriaStudy of TranspoCART19 cell therapy for patients with CD19-positive acute lymphoblastic leukemia that is resistant or refractory to treatment
SpainStudy of STK-012 Alone and Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
IrelandStudy of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back
BelgiumTesting MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment
AustriaA Study of Linvoseltamab in Adult Patients with High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
BelgiumStudy comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer
FranceA study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma
AustriaA study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene
FranceA Study Testing TUB-040 Combined with Standard Cancer Drugs for Patients with High-Grade Epithelial Serous or Endometrioid Ovarian Cancer
BelgiumA study of DT-7012 alone and in combination with pembrolizumab in patients with advanced solid tumors
FranceThe therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
